AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03262506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
Study NCT00683267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975, highly purified capsaicin
Description: One dose administered by direct instillation into the surgical site
Study NCT00683267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose administered by direct instillation into the surgical site
Study NCT04470336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Supplement
Description: Three capsules post-breakfast Three capsules post-dinner
Study NCT04470336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucosamine chondroitin
Description: Three capsules post-breakfast Three capsules post-dinner
Study NCT04470336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules post-breakfast Three capsules post-dinner
Study NCT02287493 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic Analysis
Study NCT02253836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: TPV
Study NCT02253836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: RTV
Study NCT02253836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: TAZ
Study NCT01870245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-975
Description: Intravenous multiple dose
Study NCT01870245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous multiple dose
Study NCT01578135 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Patients are to fill in a questionnaire at inclusion in registry
Study NCT01578135 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
Study NCT03648242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interruptive Clinical Decision Support
Description: An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines
Study NCT02867475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity motivation
Description: Physical activity motivation
Study NCT04451603 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical resection of the liver
Study NCT04451603 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy
Description: Y-90 radioembolization therapy is the main treatment
Study NCT04451603 — intervention group
Intervention type: DRUG
Intervention: Drug treatment
Description: Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
Study NCT00752713 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac MRI
Description: cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
Study NCT05082636 — intervention group
Intervention type: OTHER
Intervention: Observational Study ( Tissue Biopsy )
Description: control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
Study NCT00999180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A and kinesiotherapy
Description: Stroke, Botulinum Toxin
Study NCT00999180 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline and Kinesiotherapy
Description: Saline and Kinesiotherapy
Study NCT01338987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First Allogeneic Bone Marrow Transplant (BMT)
Description: First Allogeneic Bone Marrow Transplant
Study NCT01338987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First Allogeneic Bone Marrow Transplant (BMT)
Description: First Allogeneic Bone Marrow Transplant
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
Study NCT02478489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX)
Description: injectable naltrexone
Study NCT02098135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoSenso
Description: Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
Study NCT00696878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
Study NCT00696878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSH
Description: FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
Study NCT00696878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
Study NCT00696878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (rec)hCG
Description: (rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
Study NCT00696878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone administered vaginally at a dose of at least 600 mg/day.
Study NCT01278264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25%, 0.5 ml/kg
Description: Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
Study NCT01278264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25%, 0.5 ml/kg
Description: Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
Study NCT02003482 — intervention group
Intervention type: RADIATION
Intervention: Postop IMRT for head/neck cancer
Description: Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
Study NCT02003482 — intervention group
Intervention type: DEVICE
Intervention: CT for Radiation Treatment Planning
Description: Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
Study NCT03965845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenestat (CB-839)
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
Study NCT03965845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule or Tablet [Ibrance]
Description: Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
Study NCT02107534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent training (dyslexia)
Description: The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
Study NCT03950232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
Study NCT02150239 — intervention group
Intervention type: PROCEDURE
Intervention: operation
Study NCT04076475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
Study NCT01387932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HepaSphere/QuadraSphere Microspheres
Description: HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
Study NCT01387932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVA, lipiodol, doxorubicin
Description: Conventional TACE procedure using PVA, lipiodol and doxorubicin
Study NCT01443871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Subject will assigned inhale aromatherapy
Study NCT02242487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Study NCT03112135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
Study NCT03112135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Topical TXA 1 gm diluted in 200 ml saline
Study NCT03112135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: Topical adrenaline 1 mg diluted on 200 ml saline
Study NCT02233595 — intervention group
Intervention type: RADIATION
Intervention: Chemoradiation
Study NCT04370314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental prosthetics
Description: Implant-supported crowns
Study NCT04218890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin
Description: urinary sample
Study NCT01902147 — intervention group
Intervention type: OTHER
Intervention: Postoperative Quality Recovery Scale (PQRS)
Description: The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
Study NCT04961021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strabismus surgery
Description: Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
Study NCT03111160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMILE procedure using lower energy (100, 105, and 110 nJ)
Description: Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
Study NCT03111160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMILE procedure using conventional energy (115 to 150 nJ)
Description: The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
Study NCT02712177 — intervention group
Intervention type: BIOLOGICAL
Intervention: MMRV
Study NCT03825263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pressure Compression
Description: The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
Study NCT01112423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, once daily, 28 days
Study NCT01112423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 10 mg, once daily, 28 days
Study NCT01112423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 20 mg, once daily, 28 days
Study NCT01112423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study NCT02142257 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric Bypass
Description: Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
Study NCT02142257 — intervention group
Intervention type: DEVICE
Intervention: AspireAssist Aspiration Therapy
Description: AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
Study NCT04015440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBMT
Description: Individual is presented with words with some letters missing and told to complete the word.
Study NCT04015440 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Other Training
Description: Alternative to HBMT training
Study NCT04542005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: q3h albuterol
Description: Using q3h albuterol as discharge criteria from hospital
Study NCT03447236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feuerstein Program
Description: Mediated learning cognitive enhancement program
Study NCT04048668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
Study NCT04048668 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
Study NCT02379715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT02379715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F FLT
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F FLT
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
Study NCT03709901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Allograft
Description: Injection of viable allograft into the nucleus pulposus of the degenerated disc
Study NCT03709901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
Study NCT03361488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trained anesthesiogist
Study NCT01459809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE
Description: Pharmaceutical form: oral~Route of administration: oral
Study NCT01459809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN
Description: Pharmaceutical form: oral~Route of administration: oral
Study NCT03789292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P17 SC
Description: Subcutaneous injection of Adalimumab 40mg every two weeks
Study NCT03789292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P17 SC
Description: Subcutaneous injection of Adalimumab 40mg every two weeks
Study NCT03789292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira SC
Description: Subcutaneous injection of Adalimumab 40mg every two weeks
Study NCT02343302 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jackson-Pratt Drain
Description: A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain
Study NCT02343302 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-suctioning drainage
Description: A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain
Study NCT00508482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep needling
Description: Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks.
Study NCT00508482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 20-30ml, once a day before breakfast, for the whole study except the run-in period
Study NCT00508482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shallow needling
Description: Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
Study NCT03652714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglion sphenopalatine block with local anesthetic
Description: Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
Study NCT03652714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ganglion sphenopalatine block with placebo
Description: Block performed with bilaterally inserted q-tips with isotone NaCl
Study NCT00308334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: 10 mg po TID X 14 days
Study NCT00308334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Sugar pill
Description: placebo po TID x 14 days
Study NCT02536664 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Study NCT03736629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 8 weeks of Azithromycin (250 mg) once daily by mouth
Study NCT02771899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spineEOS software
Description: During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.